HER2/HER3 targeting antibodies may constitute a promising therapeutic strategy in cancer (30); hence, we decided to assess the in vivo antitumor efficacy of BEAT 2/3 in tumor xenograft experiments. The gene discussed is ERBB3; the disease is neoplasm.